Bright Minds Biosciences Inc. (DRUG) Financials

DRUG Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 218.8 million 1.8 million
March 31, 2026 223.8 million 2.7 million
Dec. 31, 2025 66.3 million 1.2 million
Sept. 30, 2025 60.6 million 1.7 million

DRUG Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -5.9 million ?
March 31, 2026 -6.8 million 864110
Dec. 31, 2025 -4.2 million 937421
Sept. 30, 2025 -910650 767751

DRUG Net Income

No data available :(

DRUG Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 217.0 million - -
March 31, 2026 221.9 million - 58897
Dec. 31, 2025 65.0 million - 76514
Sept. 30, 2025 59.5 million - 90329

DRUG Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 6.9 million
March 31, 2026 6.9 million
Dec. 31, 2025 5.7 million
Sept. 30, 2025 5.1 million

DRUG Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 6.7 million 1.6 million -
March 31, 2026 2 9.5 million 1.6 million 73240
Dec. 31, 2025 - 4.1 million 794474 72285
Sept. 30, 2025 - 3.4 million 543230 109480

DRUG Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - 14057
March 31, 2026 - 14435
Dec. 31, 2025 - 14421
Sept. 30, 2025 - 8770

DRUG

Price: $54.21

52 week price:
47.35
123.75

Earnings Per Share: -2.06 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 141500

Market Capitalization: 504.5 million

Links: